Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
News|Videos|October 29, 2026 (Updated: October 29, 2026)
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer: Phase 1–2 RMC-6236-001 Study
Author(s)Kathryn C. Arbour, MD
Daraxonrasib is being evaluated as an oral multiselective inhibitor for individuals with previously treated advanced lung cancer carrying specific genetic mutations.
Advertisement
Daraxonrasib is being evaluated as an oral multiselective inhibitor for individuals with previously treated advanced lung cancer carrying specific genetic mutations. Clinical findings show that this targeted treatment produces meaningful tumor shrinkage and durable responses in patients. The manageable safety profile and promising efficacy observed in these clinical trials support ongoing evaluation in advanced study phases.
Advertisement
Related to this article
Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
T-DXd Plus Pertuzumab Improves Outcomes in HER2+ Breast Cancer With Brain Metastases
3
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Yields Clinically Meaningful in Platinum-Resistant Ovarian Cancer
4
ASTRO Guideline Backs Hypofractionation Across Risk Groups in Localized Prostate Cancer
5